Scott Clarke, Ambagon Therapeutics CEO

A new start­up thinks it's found a key to drug­ging 'dis­or­dered' pro­teins — and it has plen­ty of cash to get start­ed

The say­ing goes ne­ces­si­ty is the moth­er of in­ven­tion — and few ar­eas of drug de­vel­op­ment are in greater need than on­col­o­gy. A new start­up is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.